

**Full-length title:** Major discrepancy between factual antibiotic resistance and consumption in South of France: analysis of 539,037 bacterial strains.

**Author list:** Ousmane Oumou Diallo<sup>1,2</sup>, Sophie Alexandra Baron<sup>1,2</sup>, Gregory Dubourg<sup>1,2</sup>, Hervé Chaudet<sup>2,3</sup>, Philippe Halfon<sup>4</sup>, Sabine Camiade<sup>4</sup>, Béatrice Comte<sup>5</sup>, Stéphanie Joubert<sup>5</sup>, Arnaud François<sup>5</sup>, Philippe Seyral<sup>6</sup>, François Parisot<sup>6</sup>, Jean-Paul Casalta<sup>3,7</sup>, Raymond Ruimy<sup>8</sup>, Christophe Maruejouis<sup>9</sup>, Jean-Christophe Achiardy<sup>9</sup>, Sophie Burignat<sup>10</sup>, Joseph Carvajal<sup>10</sup>, Edouard Delaunay<sup>10</sup>, Sandra Meyer<sup>10</sup>, Pierre-Yves Levy<sup>3,11</sup>, Patricia Roussellier<sup>12</sup>, Patrick Brunet<sup>13</sup>, Claude Bosi<sup>14</sup>, Philippe Stolidi<sup>14</sup>, Jean-Pierre Arzouni<sup>3,15</sup>, Gisele Gay<sup>15</sup>, Pierre Hance<sup>15</sup>, Philippe Colson<sup>1,2</sup>, Didier Raoult<sup>1,2\*</sup> and Jean-Marc Rolain<sup>1,2\*</sup>

**Affiliations:** <sup>1</sup> Aix Marseille Univ, IRD, APHM, MEPHI, Marseille, France, <sup>2</sup> MEPHI, Aix Marseille Université, IHU Méditerranée Infection, AP-HM, Marseille, <sup>3</sup> VITROME, Aix Marseille Université, IHU Méditerranée Infection, AP-HM, Marseille, <sup>4</sup> LBM Alphabio Marseille, <sup>5</sup> LBM Bioesterel, Cannes, <sup>6</sup> LBM Labazur Nice, <sup>7</sup> LBM Labazur Provence, <sup>8</sup> Laboratoire de bactériologie, CHU Nice, <sup>9</sup> LBM Barla, Nice, <sup>10</sup> LBM Cerballiance, Marseille, <sup>11</sup> LBM, Casamance, Aubagne, <sup>12</sup> Laboratoire de microbiologie, CH, Salon de Provence, <sup>13</sup> Laboratoire de microbiologie, CH Saint-Joseph, Marseille, <sup>14</sup> Laboratoire de microbiologie, CH, Aubagne, <sup>15</sup> LBM, Labosud Provence Biologie, Marseille

\* **Corresponding author :** Jean-Marc Rolain, Email: [jean-marc.rolain@univ-amu.fr](mailto:jean-marc.rolain@univ-amu.fr). Didier Raoult, Email: [didier.raoult@gmail.com](mailto:didier.raoult@gmail.com). Aix Marseille Univ, IRD, APHM, MEPHI, IHU Méditerranée Infection, Faculté de Médecine et de Pharmacie, 19-21 boulevard Jean Moulin, 13385 Marseille CEDEX 05, France. Phone: (33) 4 91 32 43 75.

Abstract: 250 words

Introduction: 633 words

Materials and method: 403 words

Results: 502 words

Discussion: 758 words

## Abstract

**Introduction:** The burden of antibiotic resistance is currently estimated by mathematical modeling, without real count of resistance to key antibiotics. Here we report the real rate of resistance to key antibiotics in bacteria isolated from humans during a 5 years period in a large area in southeast in France.

**Methods:** We conducted a retrospective study on antibiotic susceptibility of 539,107 clinical strains isolated from hospital and private laboratories in south of France area from January 2014 to January 2019. The resistance rate to key antibiotics as well as the proportion of bacteria classified as Difficult-to-Treat (DTR) were determined and compared with the Mann-Whitney U test, the  $\chi^2$  test or the Fisher's exact test.

**Results:** Among 539,037 isolates, we did not observe any significant increase or decrease in resistance to key antibiotics for 5 years, (oxacillin resistance in *Staphylococcus aureus*, carbapenem resistance in enterobacteria and *Pseudomonas aeruginosa* and 3<sup>rd</sup> generation cephalosporin resistance in *Escherichia coli* and *Klebsiella pneumoniae*). However, we observed a significant decrease in imipenem resistance for *Acinetobacter baumannii* from 2014 to 2018 (24.19% to 12.27%; p=0.005) and a significant increase of ceftriaxone resistance in *Klebsiella pneumoniae* (9.9% to 24,03%; p=0.001) and *Enterobacter cloacae* (24,05% to 42,05%; p=0.004). Of these 539,037 isolates, 1,604 (0.3%) had a DTR phenotype.

**Conclusion:** Over a 5-year period, we did not observe a burden of AR in our region despite a high rate of antibiotic consumption in our country. These results highlight the need for implementation of real-time AR surveillance systems which use factual data.

**Keywords:** antibiotic resistance, epidemiology, ESKAPE group, Difficult-to-treat.

## 1 INTRODUCTION

2 Even before the use of antibiotics, the phenomenon of antibiotic resistance existed<sup>1</sup>. It has  
3 evolved in several ecosystems under the influence of the use of antibiotics in animals (farm  
4 production) and in humans (healthcare-associated infections)<sup>2</sup>. It is difficult to estimate the  
5 burden of resistance to multiple antibiotics due to the use of multiple definitions and the lack  
6 of empirical data<sup>3</sup>. Many reports estimating mortality and morbidity due to antibiotic  
7 resistance have been published in recent years<sup>4</sup>. The most recent study from Cassini et al.  
8 estimated that antibiotic resistance was responsible for 33,110 deaths per year in Europe<sup>5</sup>.  
9 However, this report uses mathematical models that does not represent factually resistance to  
10 several classes of antibiotics in a given bacterial species or the real cost of antibiotic  
11 resistance on mortality<sup>3,6-8</sup>. These mathematical models, depending on the prevalence of  
12 antibiotic resistance in some countries, also use incidence ratios of a given infection to an  
13 invasive infection, and then mortality ratios, all from different literature reviews that could  
14 not be accurate to definitively estimate the number of extra deaths due to multidrug-resistance  
15 (MDR)<sup>9</sup> (<https://reflectionsipc.com/2018/11/07/amr-deaths-in-europe/>). Indeed, as it is not  
16 matter of facts to acknowledge these conclusions you need to agree with the deductive  
17 method that being a question of opinion. Therefore, these statistics are subject to  
18 controversies reporting facts may be subject to discussion on their generalization but not on  
19 their reality.

20 From an epidemiological point of view, the classification of bacteria into MDR, extensively  
21 drug-resistant (XDR) and Pandrug resistant (PDR) has an interest, but is not clinically  
22 relevant since many other antibiotics could be tested and used to treat such infections if  
23 needed<sup>10,11</sup>. Recently, some reports have suggested other definitions based on the use of first-  
24 line antibiotics in patients that are more suitable for clinicians<sup>4,12,13</sup>. Kadri et al. suggested a  
25 new definition as “difficult-to-treat” (DTR) bacterial infections i.e infections due to bacteria

26 that are *in vitro* resistant to all antibiotics tested in 3 classes of first-line antibiotics ( $\beta$ -lactams,  
27 carbapenems and fluoroquinolones)<sup>4</sup>. According to this definition, they have reported only  
28 1% of Gram-negative bacteria (GNB) classified as DTR in a large series of bacterial isolates  
29 from 173 hospitals in the USA over a 3 years period. In all cases, a therapeutic alternative was  
30 possible<sup>4</sup>.

31 Recent retrospective studies conducted in our laboratory hospital demonstrated an overall  
32 stability or a decrease in antibiotic resistance over the last decade<sup>13</sup> with only one patient who  
33 died with a DTR bacterial infection<sup>3,14</sup>. Similarly, a recent survey conducted in 251 intensive  
34 care units (ICU) in France estimated about 45 deaths attributable to antibiotic resistance  
35 without alternative treatment over a 10-years period contradicting the prediction based on  
36 mathematical models<sup>6</sup>.

37 This disparity between reality and the myth of antibiotic resistance could only be resolved by  
38 implementing efficient antibiotic resistance surveillance systems that observe in real or near-  
39 real-time the results of susceptibility testing in deceased and survivors patients, as it is already  
40 the case in our institution<sup>6</sup>.

41 Therefore, at the Marseille University Hospital Institute, using the monitoring systems  
42 implemented BALYSES (Bacterial real-time Laboratory-based Surveillance)<sup>15</sup>, MARSS  
43 (Marseille Antibiotic Resistance Surveillance System) and PACASurvE (PACA Surveillance  
44 Epidemiologic System)<sup>16</sup>, we monitor weekly the results of all strains isolated in the 4  
45 University Hospitals of Marseille (Assistance Publique Hôpitaux de Marseille) and in  
46 laboratories of the region which participate to this surveillance system for which antibiotic  
47 susceptibility testing (AST) results are available<sup>6,15,16</sup>.

48 Based on these different data sources, we retrospectively analyzed AST data from this  
49 network over a period of 5 years, focusing on the 15 most frequently isolated bacteria that are  
50 clinically relevant in human diseases. We evaluated the resistance rate of bacteria to

51 predefined key antibiotics and the evolution of this rate over time. Finally, we determined the  
52 number of DTR bacteria.

53

## 54 **MATERIAL AND METHODS**

### 55 **Clinical settings**

56 We conducted a retrospective study on AST of bacteria isolated in the Provence-Alpes-Côte  
57 d'Azur (PACA) region. This region of southeastern France has a population of 5,059,473  
58 inhabitants and an area of 31,400 km<sup>2</sup> (<https://www.insee.fr/fr/statistiques/1893198>). The  
59 data analyzed were collected from PACASurvE<sup>16</sup> and BALYSES<sup>15</sup> from January 2014 to  
60 January 2019. The data analyzed with BALYSES are those routinely produced by the AP-HM  
61 clinical microbiology laboratory, while PACASurvE analyzes are the data routinely produced  
62 by 303 different clinical microbiology laboratories, including 16 public hospital laboratories  
63 and 10 private laboratory groups from the PACA French region. In this study, we analyzed  
64 data from 267 laboratories for which AST data were available.

65

### 66 **Methodological steps**

67 The flowchart (Figure 1) describes the main methodological steps followed in this study for  
68 the 15 most common bacteria isolated in our clinical microbiology laboratories, including  
69 *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter cloacae*, *Klebsiella aerogenes*,  
70 *Proteus mirabilis*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Morganella*  
71 *morganii*, *Enterococcus faecium*, *Enterococcus faecalis*, *Staphylococcus aureus*,  
72 *Staphylococcus epidermidis*, *Streptococcus agalactiae*, *Serratia marcescens* and *Klebsiella*  
73 *oxytoca*<sup>15</sup>. To harmonize results between the different laboratories of the PACA region, key  
74 antibiotics were selected as shown in Table 1. All strains with intermediate resistance were  
75 considered resistant for statistical analysis. AST was performed according to the EUCAST  
76 (European Committee on Antimicrobial Susceptibility Testing) recommendations.

77 We also look for DTR bacteria following definition previously established by Kadri *et al.* for  
78 GNB<sup>4</sup>. Briefly, a GNB was considered as DTR if it was resistant to all cephalosporins and  
79 penicillin's+ inhibitor, all carbapenems and all fluoroquinolones. For Gram positive bacteria,  
80 the DTR definition were as follows: *Staphylococcus spp.* isolate was considered DTR if it was  
81 resistant to methicillin, gentamicin and vancomycin, whereas *Enterococcus spp.* should be  
82 resistant to at least amoxicillin, gentamicin and vancomycin to be classified as DTR. All  
83 criteria to define DTR bacteria are provided in Table 2. We then established resistance  
84 profiles for other antibiotics tested, in order to define therapeutic alternative for these bacteria.

### 85 **Statistical analysis**

86 Resistance to key antibiotics ratios were determined for the complete data set. These ratios  
87 were compared with the Mann-Whitney U test, the  $\chi^2$  test or the Fisher's exact test and the  
88 Kendall test was used for correlation. For annual trend analysis, data for the year 2019 were  
89 not included in this study.

90 A p-value <0.05 was considered statistically significant. The R software (The R Project,  
91 Auckland, New Zealand) has been used to analyze the data.

92

### 93 **RESULTS**

94 A total of 711,031 strains were isolated in all laboratories of the PACASurvE network,  
95 including 539,037 that belong to the 15 most common bacteria plus ESKAPE and had at least  
96 one key antibiotic tested (Figure 1). These data were recovered from 267 laboratories grouped  
97 in 6 hospitals laboratories and 7 groups of private laboratories. Urines (292,489; 54.26%)  
98 were the most prevalent samples followed by blood cultures (61,103; 11.34%), deeper  
99 samples (56,886; 10.55%), respiratory samples (46,966; 8.71%), skin samples (31,924;  
100 5.92%), genital samples (27,562; 5.11%), ears-nose-throat samples (17,008; 3.16%), stools  
101 (4,611; 0.56%) and cerebrospinal fluid (488; 0.09%) (Figure 2.A). The fifteen most common

102 bacterial species represented 539,037 (83.5%) isolates: *E. coli* accounted for 38% (246,353)  
103 of the isolates, followed by *S. aureus* (65,023; 10%), *K. pneumoniae* (49,733; 8%) and *E.*  
104 *faecalis* (36,857; 6%) (Table S1, Figure 2.B). These strains were isolated from 345,741  
105 patients with most women (51.5%) and an average age of 54.6 years old.

### 106 **Proportions of resistant isolates**

107 The proportion of resistant isolates for key antibiotics are shown in Table 3.

108 Globally, we observed a significant decrease in amikacin resistance from 2014 to 2018  
109 (792/16,733; 4.7% to 1,105/80,977; 1.36%,  $p=0.04$ ) for *E. coli*, *K. pneumoniae* (363/3,963;  
110 9.16% to 448/13,804; 3.25%,  $p=0.004$ ), *P. mirabilis* (76/1,390; 5.47% to 55/5,435; 1.01%,  
111  $p=0.01$ ) and *K. oxytoca* (63/651; 9.68% to 77/2,055; 3.75%,  $p=0.006$ ) (Figure 3 and Figure  
112 S1, Table S2). We also observed a significant decrease in imipenem resistance for *A.*  
113 *baumannii* from 2014 to 2018 (66/229; 28.82% to 23/185; 12.43%;  $p=0.005$ ). However, we  
114 noticed a significant increase in ceftriaxone resistance in *E. aerogenes* (38/389; 9.77% to  
115 307/1,470; 20.88%;  $p=0.001$ ), *K. oxytoca* (38/389; 9.77 % to 307/1,470; 20.88 %,  $p=0.001$ )  
116 and *E. cloacae* (187/861; 21.72% to 1,305/2,746; 47.52%;  $p=0.004$ ) whereas it remains stable  
117 in *E. coli* (2,046/21,067; 9.71 % to 7,551/84,657; 8.92 %,  $p=0.88$ ), *K. pneumoniae*  
118 (1,178/4,400; 26.77% to 3,413/14,413; 23.68%,  $p=0.89$ ), *P. mirabilis* (41/1,880; 2.18 % to  
119 88/5,749; 1.53%,  $p=0.87$ ). For *E. faecalis* we observed a significant increase in gentamicin  
120 resistance (356/2,774; 12.83% to 4,215/6,446; 65.39%,  $p=0.004$ ). We did not observe any  
121 significant increase or decrease in resistance to key antibiotics for the other bacterial species  
122 studied.

### 123 **Percentage of bacteria classified as Difficult-to-threat**

124 Of the 539,037 bacterial strains belonging to the top 15 plus ESKAPE analyzed in this study,  
125 1,604 strains (0.3%) carried a DTR phenotype (Table 4). These isolates were mostly GNB,  
126 and we identified 11 Gram positive bacteria with a DTR phenotype (11/1,604;0.68%). Among

127 GNB, *A. baumannii* was the most prevalent bacterium carrying a DTR phenotype (175;  
128 15.9%), followed by *P. aeruginosa* (902; 2.6%) and *K. pneumoniae* (372; 0.7%). However,  
129 we observed an overall evolution of non-significant DTR during our study period (Figure S2).  
130 The overall rate of DTR isolates in GNB was significantly lower (0.44% vs 1%,  $p < 10^{-5}$ ) than  
131 that observed in Kadri *et al.* study<sup>4</sup>. In both studies, *A. baumannii* was the most prevalent  
132 bacterium frequently considered as difficult-to-treat (15.33% and 18.3%,  $p = 0.24$ ), followed  
133 by *P. aeruginosa* (2.63% and 2.3%  $p = 0.21$ ) and *Klebsiella spp.* (0.66% and 1.7%,  $p < 10^{-5}$ ).

134

## 135 **DISCUSSION**

136 Nowadays, mathematical models based on predictions are of major importance in public  
137 health decision-making. While they have an interest in trying to assess what might happen in  
138 the future, they essentially require confirmation or refutation by factual data that cannot be  
139 contested. Factual data sometimes have the disadvantage of being different from one  
140 laboratory to another, but the harmonization of microbiological practices, through EUCAST  
141 or CLSI, tends to correct this discrepancy as it was the case in our study. Moreover, we were  
142 not always able to know if some isolates were from the same patient, but such bias was  
143 corrected by the mass of data analyzed. However, as our data came from a large but limited  
144 number of laboratories in the PACA region, they cannot be extrapolated to the entire region,  
145 nor to France or Europe. Thus, in our study, we did not observe any significant increase or  
146 decrease in resistance to key antibiotics, including oxacillin resistance in *S. aureus*,  
147 carbapenem resistance in enterobacteria and *P. aeruginosa*, and 3<sup>rd</sup> generation cephalosporin  
148 in *E. coli* and *K. pneumoniae*.

149 To our knowledge, this study is the world's largest series analyzing data on antibiotic  
150 resistance over a 5-year period, which allows to appreciate our local epidemiology on  
151 antibiotic resistance and to draw reliable conclusions on global trends. In literature, we found

152 only three major world series that tested more than 100,000 isolates<sup>17-19</sup> (Table 5), but they  
153 were limited to *E. coli* strains, unlike our study which focused on 15 bacterial species and  
154 their key antibiotics and were not recent studies (Table 1). Two of these studies occurred on a  
155 ten years period. The first one took place in Austria from January 1998 to December 2013,  
156 focused on 135,878 *E. coli* strains and showed a significant increase in amoxicillin, 3<sup>rd</sup>  
157 generation cephalosporin, ciprofloxacin and cotrimoxazole resistance<sup>17</sup>. The second one took  
158 place from January 2009 to October 2013 in Spain on 141,583 *E. coli*<sup>18</sup>. They showed only a  
159 change in resistance to amoxicillin and clavulanic acid that has increased over the years 20.  
160 Finally, the third study conducted in the United Kingdom from January 1996 to December  
161 2016 included 228,374 strains of *E. coli* over a 4-year period but did not analyze the level of  
162 resistance over the years<sup>19</sup>.

163 The number of strains classified as DTR in our study was very low (1,604/539.037; 0.3%) and  
164 constitutes a very rare event (<1%). This rate was lower than that observed in the study  
165 conducted by Kadri *et al.* from hospitals in the USA. This finding may be explained by our  
166 recruitment: we include both hospital and community-acquired isolates and we did not focus  
167 only on bacteremia and include all type of samples.

168 Thus, our study did not show a worrying increase in resistance to key antibiotics in our region  
169 over a 5-year period. Interestingly, despite the fact that France is considered the largest  
170 consumer of antibiotics in Europe<sup>20</sup>, and the PACA region is above the national average (31.6  
171 DDJ/1000H/J) according to the national survey

172 ([https://ansm.sante.fr/var/ansm\\_site/storage/original/application/188a6b5cf9cde90848ae9e341](https://ansm.sante.fr/var/ansm_site/storage/original/application/188a6b5cf9cde90848ae9e3419bc3d3f.pdf)  
173 [9bc3d3f.pdf](https://ansm.sante.fr/var/ansm_site/storage/original/application/188a6b5cf9cde90848ae9e3419bc3d3f.pdf)) (Figure 4), we did not observe an increase in antibiotic resistance in our study.

174 Predictive models are dependent on the belief in these models and cannot replace the facts  
175 that remain at the end. We believe that “real time” surveillance systems are the only ones  
176 capable of detecting abnormal or emerging bacterial resistance in the community and/or in

177 hospitals. This real-time monitoring of antibiotic resistance is mandatory because the main  
178 factor associated with mortality and antibiotic resistance is an inappropriate initial antibiotic  
179 treatment and not the resistance to a single antibiotic<sup>6</sup>. As mentioned above, the relevance of  
180 surveillance systems depends on the number of data collected. Nowadays, data collection is  
181 becoming increasingly simple with technological advances and the implementation of  
182 automatic computerized systems. However, the General Data Protection Regulations  
183 legislation limit access to this data, even anonymized. These data are the foundation of these  
184 monitoring systems and are essential for research and public health. Thus, they are critical to  
185 adapt empirical therapeutic strategies according to local epidemiology because antibiotic  
186 resistance is a complex phenomenon that is unpredictable<sup>21,22</sup>. Moreover, only these  
187 observations rather than prediction of a virtual future should be taken in account to make  
188 public health decision. There is an urgent need to find a balance that can guarantee the  
189 protection of patients' data, without limiting scientific research. Finally, in order to avoid the  
190 current fear of antibiotic resistance worldwide, we believe that it is urgent to set up  
191 sustainable real registers of deaths and antibiotic resistance instead of mathematical models.

192 **Funding information:** This work was supported by the French Government under the  
193 «Investissements d'avenir » (Investments for the Future) program managed by the Agence  
194 Nationale de la Recherche (ANR, fr: National Agency for Research), (reference:  
195 Méditerranée Infection 10-IAHU-03)

196 **Acknowledgment:** We want to thank CookieTrad for English correction.

197 **Transparency declaration:** The authors declare that they have no competing interests

198 **Author's contribution:**

199 OOD, SAB, DR, JMR designed the study, drafted and revised the manuscript.

200 GD, PHal, SC, BC, SJ, AF, PSe, FP, JPC, RR, CM, JCA, SB, JC, ED, SM, PYL, PR, PB, CB,

201 PSt, JPA, GG, PHan, PC performed, retrieved and analyzed microbiology analyses.

202 OOD, SAB, HC and JMR performed statistical analyses

203 All authors have read and approved the final manuscript.

204

205

206

## REFERENCES

207

- 208 1. D'Costa, V. M. *et al.* Antibiotic resistance is ancient. *Nature* **477**, 457–461 (2011).
- 209 2. Rolain, J.-M. Food and human gut as reservoirs of transferable antibiotic resistance  
210 encoding genes. *Front Microbiol* **4**, 173 (2013).
- 211 3. Abat, C. *et al.* Evaluating the Clinical Burden and Mortality Attributable to Antibiotic  
212 Resistance: The Disparity of Empirical Data and Simple Model Estimations. *Clinical*  
213 *Infectious Diseases* **65**, S58–S63 (2017).
- 214 4. Kadri, S. S. *et al.* Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US  
215 Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of  
216 Resistance to All First-line Agents. *Clinical Infectious Diseases* **67**, 1803–1814 (2018).
- 217 5. Cassini, A. *et al.* Attributable deaths and disability-adjusted life-years caused by  
218 infections with antibiotic-resistant bacteria in the EU and the European Economic Area in  
219 2015: a population-level modelling analysis. *Lancet Infect Dis* **19**, 56–66 (2019).
- 220 6. Raoult, D., Leone, M., Roussel, Y. & Rolain, J.-M. Attributable deaths caused by  
221 infections with antibiotic-resistant bacteria in France. *The Lancet Infectious Diseases* **19**,  
222 128–129 (2019).
- 223 7. de Kraker, M. E. A., Stewardson, A. J. & Harbarth, S. Will 10 Million People Die a Year  
224 due to Antimicrobial Resistance by 2050? *PLoS Med.* **13**, e1002184 (2016).
- 225 8. Cravo Oliveira Hashiguchi, T., Ait Ouakrim, D., Padget, M., Cassini, A. & Cecchini, M.  
226 Resistance proportions for eight priority antibiotic-bacterium combinations in OECD,  
227 EU/EEA and G20 countries 2000 to 2030: a modelling study. *Euro Surveill.* **24**, (2019).
- 228 9. Tacconelli, E. & Pezzani, M. D. Public health burden of antimicrobial resistance in  
229 Europe. *The Lancet. Infectious diseases* **19**, 4–6 (2019).

- 230 10. Zilberberg, M. D., Nathanson, B. H., Sulham, K., Fan, W. & Shorr, A. F. Multidrug  
231 resistance, inappropriate empiric therapy, and hospital mortality in *Acinetobacter*  
232 *baumannii* pneumonia and sepsis. *Crit Care* **20**, 221 (2016).
- 233 11. Magiorakos, A.-P. *et al.* Multidrug-resistant, extensively drug-resistant and pandrug-  
234 resistant bacteria: an international expert proposal for interim standard definitions for  
235 acquired resistance. *Clin. Microbiol. Infect.* **18**, 268–281 (2012).
- 236 12. Raoult, D. & Rolain, J.-M. The Paradigm of the Shadoks and Antibiotic Resistance. *Clin*  
237 *Infect Dis* **69**, 1641–1641 (2019).
- 238 13. Le Page, S., Dubourg, G., Baron, S. A., Rolain, J.-M. & Raoult, D. No global increase in  
239 resistance to antibiotics: a snapshot of resistance from 2001 to 2016 in Marseille, France.  
240 *Eur. J. Clin. Microbiol. Infect. Dis.* **38**, 395–407 (2019).
- 241 14. Abat, C., Fournier, P.-E., Jimeno, M.-T., Rolain, J.-M. & Raoult, D. Extremely and  
242 pandrug-resistant bacteria extra-deaths: myth or reality? *Eur. J. Clin. Microbiol. Infect.*  
243 *Dis.* **37**, 1687–1697 (2018).
- 244 15. Abat, C., Chaudet, H., Colson, P., Rolain, J. M. & Raoult, D. Real-time microbiology  
245 laboratory surveillance system to detect abnormal events and emerging infections,  
246 Marseille, France. *Emerging Infectious Diseases* **21**, 1302–1310 (2015).
- 247 16. Huart, M. *et al.* Implementation and initial analysis of a laboratory-based weekly  
248 biosurveillance system, provence-alpes-côte d'azur, France. *Emerging Infectious Diseases*  
249 **23**, 582–589 (2017).
- 250 17. Badura, A., Feierl, G., Pregartner, G., Krause, R. & Grisold, A. J. Antibiotic resistance  
251 patterns of more than 120 000 clinical *Escherichia coli* isolates in Southeast Austria,  
252 1998-2013. *Clinical Microbiology and Infection* (2015) doi:10.1016/j.cmi.2015.02.012.
- 253 18. Vihta, K. D. *et al.* Trends over time in *Escherichia coli* bloodstream infections, urinary  
254 tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of

- 255 electronic health records. *The Lancet Infectious Diseases* (2018) doi:10.1016/S1473-  
256 3099(18)30353-0.
- 257 19. Sahuquillo-Arce, J. M. *et al.* Antimicrobial resistance in more than 100,000 *Escherichia*  
258 *coli* isolates according to culture site and patient age, gender, and location. *Antimicrob.*  
259 *Agents Chemother.* **55**, 1222–1228 (2011).
- 260 20. Klein, E. Y. *et al.* Global increase and geographic convergence in antibiotic consumption  
261 between 2000 and 2015. *Proc. Natl. Acad. Sci. U.S.A.* **115**, E3463–E3470 (2018).
- 262 21. Andersson, D. I. & Hughes, D. Antibiotic resistance and its cost: is it possible to reverse  
263 resistance? *Nat. Rev. Microbiol.* **8**, 260–271 (2010).
- 264 22. Raoult, D. Alice’s living croquet theory. *Int. J. Antimicrob. Agents* **47**, 249 (2016).  
265

266

## TABLES AND FIGURES LEGEND

267

### 268 **Tables: 5**

269 Table 1: List of key antibiotics\* chosen in this study.

270 Table 2. Phenotypic Definitions of Difficult-to-Treat Resistance.

271 Table 3. Resistance rate to key antibiotics for the 15 most frequently isolated bacteria in  
272 PACA.

273 Table 4. Prevalence of strains carrying a Difficult-to-treat Resistance (DTR) phenotype  
274 isolated in PACA from January 2014 to February 2019 and comparison with study of Kadri et  
275 al.

276 Table 5: The world's largest series on the study on antibiotic resistance.

### 277 **Figures: 4**

278 Figure 1. Flow-chart data-analysis. AST: Antibiotic Susceptibility Testing.

279 Figure 2

280 **A.** Presentation of the top 15 most frequently isolated bacteria in our surveillance systems  
281 (BALYSES and PACASurvE) between 2014 to 2019.

282 **B.** The different types of samples (for only the laboratories that notify them)

283 Figure 3. Evolution of resistance percentage of key antibiotics in bacterial species isolated  
284 from January 2014 to December 2018.

285 Figure 4. Third Cephalosporin generation consumption and resistance (%) worldwide

286

### 287 **Supplementary data: 4**

288 Table S1: Presentation of the different bacterial species isolated from our surveillance system  
289 from January 2014 to February 2019 (N=711,031).

290 Table S2: Trend in antibiotic resistance of the species studied for the full years 2014 to 2018.

291 Figure S1. Evolution of resistance percentage of key antibiotics in bacterial species isolated  
292 by the different laboratories included in our study from January 2014 to December 2018.

293 **A.** *E. coli*; **B.** *P. mirabilis*; **C.** *E. cloacae*; **D.** *E. aerogenes*; **E.** *K. oxytoca*; **F.** *S. marcescens*;

294 **G.** *K. pneumoniae*; **H.** *M. morgani*; **I.** *E. faecalis*; **J.** *E. faecium*; **K.** *S. epidermidis*; **L.** *S.*

295 *agalactiae*

296 Figure S2. Evolution of the number of strains carrying a DTR phenotype between 2014 and  
297 2018.

298

299 Table 1: List of key antibiotics\* chosen in this study

<i>E. coli/ P.mirabilis</i>	<i>Klebsiella spp./ Enterobacter spp.</i>	<i>A. baumannii/ P. aeruginosa</i>	<i>Enterococcus spp.</i>	<i>Staphylococcus spp.</i>	<i>S. agalactiae</i>
Amoxicillin	Ceftriaxone	Ceftazidime	Amoxicillin	Oxacillin	Amoxicillin
Amoxicillin- clavulanic acid	Imipenem	Imipenem	Gentamicin	Cotrimoxazole	Cotrimoxazole
Ceftriaxone	Amikacine	Ciprofloxacin	Vancomycin	Vancomycin	Vancomycin
Imipenem	Ciprofloxacin				
Ciprofloxacin					
Amikacin					

300

301

302

303

304

\* **Alternative key antibiotics:** Ticarcillin or Ampicillin for Amoxicillin, Ticarcillin–  
clavulanic acid or Tazocillin for Amoxicillin-clavulanic acid, cefepim for ceftriaxone,  
Gentamicin for Amikacin, cefoxitin for oxacillin.

305  
306

Table 2. Phenotypic Definitions of Difficult-to-Treat Resistance.

Gram negative bacteria	$\beta$ -lactam	Extended-spectrum cephalosporin	Carbapenems	Fluoroquinolones
<i>Escherichia coli</i> <i>Klebsiella spp</i> <i>Enterobacter spp</i> <i>Proteus mirabilis</i> <i>Serratia marcescens</i> <i>Morganella morganii</i>	Aztreonam, Piperacillin-tazobactam	Cefepime, Ceftriaxone, Cefotaxime	Imipenem, Meropenem Doripenem Ertapenem	Ciprofloxacin, Levofloxacin, Moxifloxacin
<i>Acinetobacter baumannii</i>	Piperacillin-tazobactam	Ceftazidime, Cefepime	Imipenem, Meropenem Doripenem	Ciprofloxacin, Levofloxacin, Moxifloxacin
<i>Pseudomonas aeruginosa</i>	Aztreonam, Piperacillin-tazobactam	Ceftazidime, Cefepime	Imipenem, Meropenem Doripenem	Ciprofloxacin, Levofloxacin
Gram positive bacteria	$\beta$ -lactam	Glycopeptides		Aminosides
<i>Enterococcus faecium</i> <i>Enterococcus faecalis</i>	Amoxicillin	Vancomycin, Teicoplanin		Gentamicin, Tobramycin
<i>Staphylococcus spp</i>	Oxacilline	Vancomycin, Teicoplanin		Gentamicin, Tobramycin
<i>Streptococcus agalactiae</i>	Amoxicillin	Vancomycin, Teicoplanin		Gentamicin

307  
308  
309  
310  
311  
312

313 Table 3. Resistance rate to key antibiotics for the 15 most frequently isolated bacteria in  
 314 Provence-Alpes-Côte d'Azur region.  
 315

	Number of infections	Rate %
<i>Escherichia coli</i>		
Amoxicillin-resistance	140,588	50.4
Amoxicillin-clavulanic acid resistance	59,909	25.5
3GC-resistance	25,650	9.5
Ciprofloxacin resistance	37,549	14.9
Carbapenem resistance	202	0.2
Amikacin resistance	6,126	2.5
<i>Proteus mirabilis</i>		
Amoxicillin resistance	8,272	40.7
Amoxicillin-clavulanic acid resistance	1,811	10.2
3GC-resistance	353	1.9
Ciprofloxacin resistance	2,248	11.9
Carbapenem resistance	195	2.4
Amikacin resistance	406	2.4
<i>Klebsiella pneumoniae</i>		
3GC-resistance	12,404	25.8
Carbapenem resistance	600	1.9
Amikacin resistance	2,326	5.2
<i>Klebsiella oxytoca</i>		
3GC-resistance	732	10.1
Carbapenem resistance	30	0.5
Amikacin resistance	323	4.7
<i>Klebsiella aerogenes</i>		
3GC-resistance	811	16.9
Carbapenem resistance	76	1.6
Amikacin resistance	248	4.1
<i>Enterobacter cloacae</i>		
3GC-resistance	3,180	36.1
Carbapenem resistance	179	1.2

Amikacin resistance	797	5.6
<i>Acinetobacter baumannii</i>		
3GC-resistance	508	50.0
Carbapenem resistance	225	20.3
Ciprofloxacin resistance	456	47.0
Amikacin resistance	159	25.6
<i>Pseudomonas aeruginosa</i>		
3GC-resistance	4,673	13.2
Carbapenem resistance	7,191	19.6
Ciprofloxacin resistance	5,924	21.2
Amikacin resistance	2,544	9.2
<i>Enterococcus faecalis</i>		
Amoxicillin resistance	84	0.3
Gentamicin resistance	7,400	32.1
Vancomycin resistance	34	0.1
<i>Enterococcus faecium</i>		
Amoxicillin resistance	3,168	82.1
Gentamicin resistance	1,856	54.1
Vancomycin resistance	100	2.9
<i>Staphylococcus aureus</i>		
Methicillin resistance	9,295	16.9
Cotrimoxazole resistance	564	1.1
Vancomycin resistance	0	0.0
<i>Streptococcus agalactiae</i>		
Penicillin resistance	7	0.07
Cotrimoxazole resistance	184	3.1
Vancomycin resistance	0	0.0

(Number of strains resistant/Number of AST\*\*)

316  
317

Table 4. Prevalence of strains carrying a Difficult-to-treat Resistance (DTR) phenotype isolated in Provence-Alpes-Côte d’Azur from January 2014 to February 2019 and comparison with the study of Kadri et al.

Bacterial strains	Number of DTR (Number of strains)	Rate (%)	173 hospitals in USA (Kadri et al. 2018)	P_value
<i>Escherichia coli</i>	85 (246, 353)	0.03	12/28,640 (0.04)	0.64
<i>Klebsiella spp. (K. pneumoniae and K. oxytoca)</i>	383 (57,620)	0.66	155/9,168 (1.7)	< 10 <sup>-5</sup>
<i>Enterobacter spp. (K. aerogenes* and E. cloacae)</i>	39 (21,602)	0.18	20/3,221 (0.6)	< 10 <sup>-5</sup>
<i>Proteus mirabilis</i>	1 (18,064)	0.006	NA	
<i>Serratia marcescens</i>	3 (4,437)	0.07	NA	
<i>Morganella morganii</i>	5(4,935)	0.1	NA	
<i>Pseudomonas aeruginosa</i>	902 (34,966)	2.6	101/4,493 (2.3)	0.21
<i>Acinetobacter baumannii</i>	175 (1,098)	15.9	183/999 (18.3)	0.24
<i>Enterococcus faecalis</i>	3 (36,857)	0.008	NA	
<i>Enterococcus faecium</i>	5 (4,871)	0.10	NA	
<i>Staphylococcus aureus</i>	0 (65,023)	0	NA	
<i>Staphylococcus epidermidis</i>	3 (28,527)	0.01	NA	
<i>Streptococcus agalactiae</i>	0 (14,684)	0	NA	
Total (comparison with Kadri et al.)	<b>1,584 (361,639)</b>	<b>0.44</b>	<b>1.01 (471/46,521)</b>	< 10 <sup>-5</sup>
<b>Total</b>	<b>1, 604 (539,037)</b>	<b>0.3</b>	NA	


\*Previously *Enterobacter aerogenes*, having resistance similar to *Enterobacter spp* species.

Table 5. The world's largest series on the study on antibiotic resistance.

Country	Number Of Strains	Samples	Year	Reference
Austria	135,878 <i>E. coli</i>	Blood, Genital tract, Urinary tract, Respiratory tract, wounds and others	January 1998 to December 2013	(17)
Spain	141,583 <i>E. coli</i>	Abscesses, Digestive system, Urine, Genitourinary system, Medical devices, Bones and deep tissues, Prostatic fluid, Respiratory system, Blood, and skin and soft tissues.	January 2009 to October 2013	(18)
United Kingdom	228,376 <i>E. coli</i>	Blood and Urine	January 1998 to December 2016	(19)
France (Provence-Alpes-Cote-d'Azur)	539,037 isolates	Urine, Blood, Deep, Skin, otorhinolaryngological, cerebrospinal fluid, Genital tract, Stools and Others	January 2014 to February 2019	This study

**\*Top 15 bacterial species**

- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Klebsiella oxytoca*
- *Enterobacter cloacae*
- *Enterobacter aerogenes*
- *Acinetobacter baumannii*
- *Pseudomonas aeruginosa*
- *Proteus mirabilis*
- *Morganella morganii*
- *Serratia marcescens*
- *Enterococcus faecium*
- *Enterococcus faecalis*
- *Staphylococcus aureus*
- *Staphylococcus epidermidis*
- *Streptococcus agalactiae*



**Figure 1. Flow chart of raw antibiogram data available January 2014-February 2019)**




Figure 2: **A.** Presentation of the top 15 most frequently isolated bacteria in our surveillance systems (BALYSES and PACASurvE) between 2014 to 2019.

**B.** The different types of samples (for only the laboratories that notify them).




Figure 3. Evolution of resistance percentage of key antibiotics in bacterial species isolated from January 2014 to December 2018.






Figure 4. Third Cephalosporin generation consumption and resistance (%) worldwide

**\*Top 15 bacterial species**


- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Klebsiella oxytoca*
- *Enterobacter cloacae*
- *Klebsiella aerogenes*
- *Acinetobacter baumannii*
- *Pseudomonas aeruginosa*
- *Proteus mirabilis*
- *Morganella morganii*
- *Serratia marcescens*
- *Enterococcus faecium*
- *Enterococcus faecalis*
- *Staphylococcus aureus*
- *Staphylococcus epidermidis*
- *Streptococcus agalactiae*




A




B





## Third Cephalosporins generation consumption and resistance in *E. coli* (%) worldwide.


### 1. Worldwide



### 2. France, Italy and Greece




### 3. France



## Carbapenem consumption and resistance (%) in *K. pneumoniae*

### 1. Worldwide



### 2. France, Italy and Greece



### 3. France

